Sustained creatinine renal clearance decreased
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB16165 | Finerenone | A nonsteroidal mineralocorticoid receptor antagonist indicated to lower the risk of eGFR decline, end stage kidney disease, cardiovascular death, heart attack, and hospitalization for heart failure in chronic kidney disease associated with type 2 diabetes. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB16165 | Finerenone | Cytochrome P450 3A4 | enzyme |
| DB16165 | Finerenone | Cytochrome P450 2C8 | enzyme |
| DB16165 | Finerenone | Serum albumin | carrier |
| DB16165 | Finerenone | Mineralocorticoid receptor | target |
| DB16165 | Finerenone | Cytochrome P450 1A1 | enzyme |
| Drug | Drug Name | Phase | Status | Count |
|---|